Global fintech and funding innovation ecosystem

Artificial Pancreas Is First To Raise $1 Million Under New Crowdfunding Rules (in the US)

share save 171 16 - Artificial Pancreas Is First To Raise $1 Million Under New Crowdfunding Rules (in the US)

MIT Technology | by Andrew Rosenblum | July 29, 2016

Artificial pancreas 285x300 - Artificial Pancreas Is First To Raise $1 Million Under New Crowdfunding Rules (in the US)

When Beta Bionics needed idealistic investors it found them on the Web.

A company creating an “artificial pancreas” for diabetics this week became the first startup to raise $1 million using new type of online stock sale open to the public at large.

Beta Bionics, a startup created by Boston University biomedical engineer Ed Damiano, hit the benchmark Wednesday night after 775 members of the public put up an average of $1,300 each to back its idea for a new kind of pacemaker for diabetics.

The company sold shares on the crowdfunding portal Wefunder, which along with sites like StartEngine and Flashfunders, is taking advantage of securities regulations that since May have let private companies easily sell shares directly to the public, not only professional investors.

Beta Bionics could become a test case for crowdfunding and the tech industry’s position that the public should be able to invest in risky startups. Companies raising funds using the new rules include Legion M, “the first Hollywood studio owned by fans,” a brewery in Texas, and a company developing novelty genetically modified organisms.

The new process, known as “regulation crowdfunding,” represents the latest easing of securities laws set in motion by the JOBS Act of 2012 and is meant to modernize investing.

A prototype of a bionic pancreas, the iLet, developed at Boston University.


The artificial pancreas technology was developed by Damiano, whose teenage son has type 1 diabetes and has to inject himself with insulin or risk going into a diabetic coma. While some diabetics already use implanted sensors to read levels of glucose in their blood, Beta Bionics’s device, called the iLet, would also automatically pump insulin into the body when needed, creating a hands-off system.

Beta Bionics opted for the crowdfunding route because it is a “public benefit corporation,” meaning the company’s charter is to act in the best interests of people with type 1 diabetes, including at the expense of short-term profits. That meant it was looking for investors motivated by idealism or who have been affected by type 1 diabetes—which, if managed poorly, can peel years off a person’s life.

Many investors turned out to be scientists or people involved with diabetes research, like Gabriel Smolarz, a clinical assistant professor of medicine at Rutgers University’s Robert Wood Johnson Medical School. Smolarz has two nephews and a sister-in-law with type 1 diabetes. "In my mind, it’s akin to a self-driving car,” he says. “It sounds great—a lot of potential, you’re eliminating human error—but at the same time you’re eliminating human control."

Michelle Faulkner, who works at a Boston public relations firm that represents Wefunder, also invested, buying $1,000 in shares. She says her fiancé suffered diabetes-related kidney failure and then a fatal heart attack two years ago at the age of 46. “He had an outdoor job, he was an electrician,” says Faulkner. “He didn’t want to carry his meter around with him—he didn’t feel it was practical. He tried to do it on his own, based on how he was feeling, and that just doesn’t work. It’s not the kind of disease you can handle using your gut feel.”

Nicholas Tommarello, cofounder and CEO of Wefunder, estimated that since May, private companies have raised more than $5 million under the new crowdfunding rules. That’s a fairly slow start for the idea, although Tommarello notes that about 29 percent of investors have invested just the $100 minimum.

“The idea is having lots of little people making small investments, as opposed to large investments made by the traditional financial infrastructure,” says Marc A. Leaf, a law partner at Drinker, Biddle, and Reath who previously served on the executive staff of the Securities and Exchange Commission.

He says it remains to be seen whether the collective instincts of the public will prove better at picking winners than professional technology investors. “We can query whether in fact crowds are wise,” says Leaf.

Bioengineer Edward Damiano developed an “artificial pancreas” after his son, David, was diagnosed with type 1 diabetes.

By raising $1 million, Beta Bionics hit the maximum amount companies are legally able to raise with regulation crowdfunding in a single year. Leaf, who recently analyzed 50 companies seeking crowdfunding, says he believes it is the first company to have done so.

Continue to the full article --> here


ncfa logo 100.gif?zoom=1 - Artificial Pancreas Is First To Raise $1 Million Under New Crowdfunding Rules (in the US)

The National Crowdfunding Association of Canada (NCFA Canada) is a cross-Canada non-profit actively engaged with both social and investment crowdfunding stakeholders across the country. NCFA Canada provides education, research, leadership, support and networking opportunities to over 1300+ members and works closely with industry, government, academia, community and eco-system partners and affiliates to create a strong and vibrant crowdfunding industry in Canada. Learn more at

share save 171 16 - Artificial Pancreas Is First To Raise $1 Million Under New Crowdfunding Rules (in the US)

Leave a Reply

Your email address will not be published. Required fields are marked *

12 − seven =